4.95MMarket Cap-480P/E (TTM)
0.2199High0.2002Low241.43KVolume0.2002Open0.2036Pre Close50.64KTurnover1.16%Turnover RatioLossP/E (Static)23.46MShares1.510052wk High1.09P/B4.40MFloat Cap0.141452wk Low--Dividend TTM20.84MShs Float80136000.0000Historical High--Div YieldTTM9.68%Amplitude0.1414Historical Low0.2090Avg Price1Lot Size
ReShape Lifesciences Stock Forum
newsfile· 22 mins ago
On July 10, 2024, ReShape Lifesciences® (Nasdaq: RSLS), a company in weight loss and metabolic health solutions, announced its entry into a definitive merger agreement with Vyome Therapeutics, Inc., a private clinical-stage company focused on immuno-inflammatory and rare diseases. This merger pinpoin...
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
ReShape Lifesciences has entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys for $5.16 million.
The all-stock merger will see Vyome and ReShape combine, focusing on immuno-inflammatory diseases. Post-merger, ReShape will be renamed Vyome Holdings and will trade under the Nasdaq ticke...
No comment yet